Autopsy report · NCT03497234

Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test

“Business Strategic Decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Hologic, Inc.

Sponsor type

Industry

Conditions

Intra-Amniotic Infection of Foetus

Interventions

Perilynx Analyzer to measure AF and VF fluid

Participants

0

Sites

5

Countries

United States

Trials that died the same way

• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (99% match in meaning)
• CD8 Minibody Repeatability Study
  “Strategic decision” (92% match in meaning)
• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
  “Strategic corporate decision” (91% match in meaning)
• A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome
  “Company's strategic decision” (89% match in meaning)
• A Study of RBI-4000 in Healthy Participants
  “Strategic business decision (not related to safety, efficacy, or quality)” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.